A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Inclusion Criteria:

Participants are eligible to be included in the study only if all the following criteria apply:

• Participant has provided informed consent before initiation of any study specificactivities/procedures.

• Must have been eligible to receive and have received IP (dazodalibep or placebo) andcompleted the study (through Week 48) in one of the phase 3 SS dazodalibep studies (HZNP-DAZ-301, or HZNP-DAZ-303).

• Must be able to receive Dose 1 of this LTE study at the Week 48 Visit (+28 days) forthe prior pivotal phase 3 SS dazodalibep studies (HZNP DAZ-301, or HZNP DAZ-303).

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

• Clinically significant active infection at Day 1, in the opinion of theInvestigator, including ongoing and chronic infection requiring antibiotics orantiviral medication.

• Planned participation in another clinical study with an IP or procedure during theLTE study. Other investigational procedures and participation in observationalresearch studies while participating in this study are excluded.

• Any condition or change in health status observed or reported during the phase 3 SSstudies (HZNP-DAZ-301, or HZNP-DAZ-303) that, in the opinion of the Investigator orthe Sponsor, would interfere with evaluation and interpretation of participantsafety or alter the risk-benefit associated with IP administration.

• Planned surgeries or hospitalizations that, in the opinion of the Investigator orthe Sponsor, would interfere with evaluation and interpretation of participantsafety.

• Individuals who plan to receive live (attenuated) vaccine during the LTE study.

• Female participants of childbearing potential unwilling to use protocol-specifiedmethod of contraception during treatment and for an additional 12 weeks after thelast dose of investigational product.

• Female participants who are pregnant or lactating or planning to become pregnantduring the study.

• Participant has known sensitivity to any of the products or components to beadministered during dosing.

• Participant likely to not be available to complete all protocol-required studyvisits or procedures, and/or to comply with all required study procedures to thebest of the participant and investigator's knowledge.

• History or evidence of any other clinically significant disorder, condition, ordisease that, in the opinion of the investigator or Amgen physician, if consulted,would pose a risk to participant safety or interfere with the study evaluation.